Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- apixaban
- mitotane
Interactions between your drugs
mitotane apixaban
Applies to: mitotane, apixaban
Theoretically, coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of apixaban, which is a substrate of both the isoenzyme and the efflux transporter. When apixaban was coadministered with 600 mg/day of rifampin, a dual P-gp and potent CYP450 3A4 inducer, mean apixaban peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 42% and 54%, respectively. No data are available for use with other, less potent CYP450 3A4 and/or P-gp inducers.
References (6)
- (2012) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Canada Inc
- (2021) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb, SUPPL-34
- (2024) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Pharmaceuticals Ltd
- (2025) "Product Information. Apixaban (apixaban)." Teva UK Ltd
- (2024) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Australia Pty Ltd
- (2022) "Product Information. ACH-Apixaban (apixaban)." Accord Healthcare Inc
Drug and food interactions
mitotane food
Applies to: mitotane
ADJUST DOSING INTERVAL: Fat-rich food enhances the absorption of mitotane. One study evaluated blood levels of mitotane (o,p'-DDD) after subjects ingested a single dose of 2 g administered using various delivery vehicles (e.g., tablets, granules, milk, chocolate or oil emulsion). Mitotane plasma levels were significantly higher for milk, chocolate, and oil emulsion when compared to those who received tablets or granules alone. In the same study, mitotane levels were evaluated in subjects following long-term treatment (total dose of 200 g over 30 to 60 days) in tablet, oil emulsion, or milk formulations. Significantly higher mean plasma levels were recorded in subjects who received mitotane as an oil emulsion or mixed in milk, when compared to tablets alone. Additionally, the recovery of o,p'-DDD from the feces was about 5 times higher in subjects who received tablets alone, suggesting absorption was reduced when compared to subjects who received mitotane mixed with a fat-rich vehicle (e.g., oil emulsion or milk).
GENERALLY AVOID: Concomitant use of mitotane with central nervous system (CNS) depressants, including alcohol, may potentiate adverse effects such as somnolence and sedation.
MANAGEMENT: According to product labeling, mitotane tablets should be taken during meals containing fat-rich food (e.g., milk, chocolate, or oil) and with a full glass of water. Patients should be advised to avoid or limit consumption of alcohol and to avoid activities requiring mental alertness such as driving or operating hazardous machinery until they know how the medication affects them.
References (4)
- (2023) "Product Information. Lysodren (mitotane)." HRA Pharma America
- (2023) "Product Information. Lysodren (mitotane)." Medunik Canada
- (2023) "Product Information. Lysodren (mitotane)." HRA Pharma UK & Ireland Ltd
- Moolenaar AJ, van Slooten H, van Seters AP, Smeenk D (2023) Blood levels of o,p-DDD following administration in various vehicles after a single dose and during long-term treatment https://link.springer.com/article/10.1007/BF00258213
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Eliquis
Eliquis (apixaban) is used to reduce the risk of stroke and systemic embolism in patients with ...
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Lovenox
Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs ...
Coumadin
Coumadin is used to prevent heart attacks, strokes, and blood clots in veins and arteries. Learn ...
Brilinta
Brilinta (ticagrelor) is used to lower your risk of having a stroke or serious heart problems after ...
Pradaxa
Pradaxa (dabigatran) is used to prevent stroke and blood clots in patients with atrial ...
Ecotrin
Ecotrin is used for angina, angina pectoris prophylaxis, ankylosing spondylitis, antiphospholipid ...
Jantoven
Jantoven is used for antiphospholipid syndrome, chronic central venous catheterization, deep vein ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.